Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
- J. Baselga, M. Campone, +18 authors G. Hortobagyi
- Medicine
- The New England journal of medicine
- 8 February 2012
BACKGROUND
Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR… Expand
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
- S. Swain, J. Baselga, +11 authors J. Cortés
- Medicine
- The New England journal of medicine
- 18 February 2015
BACKGROUND
In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line… Expand
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
- D. Yardley, S. Noguchi, +17 authors H. Rugo
- Medicine
- Advances in Therapy
- 25 October 2013
IntroductionEffective treatments for hormone-receptor-positive (HR+) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast… Expand
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
- J. Baselga, V. Semiglazov, +17 authors H. Rugo
- Medicine
- Journal of clinical oncology : official journal…
- 1 June 2009
PURPOSE
Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance to endocrine therapy, and… Expand
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2…
- C. Le Tourneau, J. Delord, +20 authors X. Paoletti
- Medicine
- The Lancet. Oncology
- 1 October 2015
BACKGROUND
Molecularly targeted agents have been reported to have anti-tumour activity for patients whose tumours harbour the matching molecular alteration. These results have led to increased… Expand
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
- E. Thomas, H. Gómez, +14 authors H. Roché
- Medicine
- Journal of clinical oncology : official journal…
- 20 November 2007
PURPOSE
Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent activity in these patients and has… Expand
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind,…
- J. Baselga, S. Im, +22 authors M. Campone
- Medicine
- The Lancet. Oncology
- 1 July 2017
BACKGROUND
Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study assessed the efficacy of… Expand
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
- M. J. van den Bent, A. Brandes, +14 authors T. Gorlia
- Medicine
- Journal of clinical oncology : official journal…
- 10 March 2009
PURPOSE
Approximately 50% of glioblastomas (GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% of instances,… Expand
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
- T. Batchelor, P. Mulholland, +18 authors M. J. van den Bent
- Medicine
- Journal of clinical oncology : official journal…
- 10 September 2013
PURPOSE
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of… Expand
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
- P. Farmer, H. Bonnefoi, +17 authors M. Delorenzi
- Medicine
- Nature Medicine
- 2009
To better understand the relationship between tumor-host interactions and the efficacy of chemotherapy, we have developed an analytical approach to quantify several biological processes observed in… Expand